The last comparison group was patients with EBV-laryngeal cancer versus a group of healthy EBV volunteers, in which we observed a lack of statistical significance only in the population of CD19+CD69+ B lymphocytes, as well as in the IgG VCA EBV quantitative group (Table 5). This evidence concerns the gene CD19 and laryngeal carcinoma.